Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aditi Kadakia

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Postgraduate Medicine|December 1, 2016
Buprenorphine transdermal system utilizationLaura Wallace, Aditi Kadakia
Journal of Pain Research|May 17, 2018
The epidemiology of outpatient pain treatment in pediatricsStacy Baldridge, Laura Wallace, Aditi Kadakia
Journal of Medical Economics|October 14, 2021
Hospitalization risk in pediatric patients with bipolar disorder treated with lurasidone vs. other oral atypical antipsychotics: a real-world retrospective claims database studyAditi Kadakia, Carole Dembek, Yi Liu, et al.
The Journal of Pain|April 2, 2015
A retrospective cohort study of long-term immediate-release hydrocodone/acetaminophen use and acetaminophen dosing above the Food and Drug Administration recommended maximum daily limit among commercially insured individuals in the United States (2008-2013)Angela DeVeaugh-Geiss, Aditi Kadakia, Howard Chilcoat, et al.
Journal of Pain Research|August 11, 2017
Real-world utilization of once-daily extended-release abuse deterrent formulation of hydrocodone: a comparison with the pre-approval randomized clinical trialsLouise Taber, T Christopher Bond, Xuezhe Wang, et al.
The Journal of Clinical Psychiatry|August 9, 2023
The Lifetime Burden of Schizophrenia as Estimated by a Government-Centric Fiscal Analytic FrameworkRui Martins, Aditi Kadakia, G Rhys Williams, et al.
The American Journal of Managed Care|September 19, 2022
Burden of EPS in commercial patients with schizophrenia initiating atypical antipsychoticsAditi Kadakia, Brenna L Brady, Carole Dembek, et al.
Journal of Medical Economics|December 16, 2021
The incidence and economic burden of extrapyramidal symptoms in patients with schizophrenia treated with second generation antipsychotics in a Medicaid populationAditi Kadakia, Brenna L Brady, Carole Dembek, et al.
American Journal of Clinical Oncology|April 24, 2013
CMF-regimen preferred as first-course chemotherapy for older and sicker women with breast cancer: Findings from a SEER-Medicare-based population studyAditi Kadakia, Suja S Rajan, Susan Abughosh, et al.
BMJ Open|August 1, 2024
A real-world data analysis of electronic health records to investigate the associations of predominant negative symptoms with healthcare resource utilisation, costs and treatment patterns among patients with schizophreniaRashmi Patel, Carole Dembek, Yida Won, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Postgraduate Medicine|December 1, 2016
Buprenorphine transdermal system utilizationLaura Wallace, Aditi Kadakia
Journal of Pain Research|May 17, 2018
The epidemiology of outpatient pain treatment in pediatricsStacy Baldridge, Laura Wallace, Aditi Kadakia
Journal of Medical Economics|October 14, 2021
Hospitalization risk in pediatric patients with bipolar disorder treated with lurasidone vs. other oral atypical antipsychotics: a real-world retrospective claims database studyAditi Kadakia, Carole Dembek, Yi Liu, et al.
The Journal of Pain|April 2, 2015
A retrospective cohort study of long-term immediate-release hydrocodone/acetaminophen use and acetaminophen dosing above the Food and Drug Administration recommended maximum daily limit among commercially insured individuals in the United States (2008-2013)Angela DeVeaugh-Geiss, Aditi Kadakia, Howard Chilcoat, et al.
Journal of Pain Research|August 11, 2017
Real-world utilization of once-daily extended-release abuse deterrent formulation of hydrocodone: a comparison with the pre-approval randomized clinical trialsLouise Taber, T Christopher Bond, Xuezhe Wang, et al.
The Journal of Clinical Psychiatry|August 9, 2023
The Lifetime Burden of Schizophrenia as Estimated by a Government-Centric Fiscal Analytic FrameworkRui Martins, Aditi Kadakia, G Rhys Williams, et al.
The American Journal of Managed Care|September 19, 2022
Burden of EPS in commercial patients with schizophrenia initiating atypical antipsychoticsAditi Kadakia, Brenna L Brady, Carole Dembek, et al.
Journal of Medical Economics|December 16, 2021
The incidence and economic burden of extrapyramidal symptoms in patients with schizophrenia treated with second generation antipsychotics in a Medicaid populationAditi Kadakia, Brenna L Brady, Carole Dembek, et al.
American Journal of Clinical Oncology|April 24, 2013
CMF-regimen preferred as first-course chemotherapy for older and sicker women with breast cancer: Findings from a SEER-Medicare-based population studyAditi Kadakia, Suja S Rajan, Susan Abughosh, et al.
BMJ Open|August 1, 2024
A real-world data analysis of electronic health records to investigate the associations of predominant negative symptoms with healthcare resource utilisation, costs and treatment patterns among patients with schizophreniaRashmi Patel, Carole Dembek, Yida Won, et al.
Pageof 2